novo nordisk tirzepatide Administration Anounces Landmark GLP-1 Pricing Agreement with Eli Lilly and Novo Nordisk's CagriSema Delivers 23%

Research indicates that discontinuing GLP-1 medications after achieving weight loss goals often leads to weight regain

Semaglutide binds to GLP-1 receptors in several areas of the body, including the brain, pancreas, and gastrointestinal tract

This selective targeting underpins their efficacy in enhancing insulin secretion, inhibiting glucagon release, and promoting metabolic control in diabetes management (29)

These observations suggest that the actions of DSIP on substance P, beta-endorphin, and corticosterone are indicative of a wider array of biochemical modifications, proposing that DSIP may trigger a cascade of molecular events that may facilitate its stress-modulatory functions

While its a game-changer for many, side effects do exist and can vary from person to person

doi: 10.7759/cureus.6466